Cytokinetics, Inc. (CYTK)

[Solantey]

Recent buyers will continue to accumulate cheap shares. Major brokerages are getting their clients in here. Upgrades on the horizon.

Substantially oversold with a shrinking float and millions of shares needed to cover as positive news is released.

Needham has a $15.00 price target but I think $10.00 within three months is more realistic.

There's always the possibility that Amgen or Astellas could take a run at buying the company. Sometimes it's better to own than rent.

The game continues.

p.s. The funds that wished they'd bought at $6.00 before it went to $13.00 are taking advantage of the cheap shares. History does tend to repeat.